Qlife Aps

Qlife Aps was established in Copenhagen, Denmark by Thomas Warthoe, Peter Warthoe, Lars Bangsgaard and Ebbe Finding. The founders have spent the last 20 years in the IVD (In-Vitro Diagnostic) industry building small high-tech medical devices to partner with leading IVD companies and have gained solid know-how and experience in product development, regulatory approvals and business operations.

A professional board of directors was established in 2019 in connection with a capital injection of 5 MDKK from Danish Preseed Ventures, KMD Ventures and two Swedish business angels.
A pre-IPO was carried out in August 2019 and raised 18 MSEK for the company.

Qlife Holding AB

In 2019 the company obtained the ISO 13485:2016 certification, thus Qlife lives up to all requirements for manufacturing and selling in-vitro diagnostic analyzers and reagents. The first capsules for the Egoo System were CE marked for professional use early 2020.

The company has filed for patent protection for key elements of its technology. Today, the company organization consists of 15 people.

Qlife Holding AB was incorporated in October 2019, and is the sole owner of Qlife Aps, through a non-cash issue.

Qlife Holding AB finalised an IPO in february 2020 raising 55MSEK. The company is listed on Nasdaq, First North Growth Market, Stockholm as from March 2, 2020.

Strategy and Vision

Qlife is a high-tech medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it the most.

The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient’s doctor, clinic or hospital via smartphone and computer.

The short-term strategy is to launch the system into well-defined market segments of chronically ill patients, where the need for regular home monitoring is high, while further biomarkers are being developed. Over time, our strategy will expand into the lucrative consumer self-testing market and give people the opportunity to take a more proactive approach to their health with the help of clinical data. Market launch will first occur in the Nordic countries, followed by Europe, USA and ROW.